Schizophrenia Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Multiple Oral Dose Study Assessing the Safety and Tolerability of SEP-363856 in Japanese Subjects With Schizophrenia
Verified date | April 2022 |
Source | Sumitomo Pharma Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multiple oral dose, randomized, double-blind, placebo-controlled study assessing the safety, tolerability and pharmacokinetics (PK) of SEP-363856 when administered qhs to Japanese subjects with schizophrenia.
Status | Completed |
Enrollment | 13 |
Est. completion date | August 7, 2020 |
Est. primary completion date | August 7, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Subjects who voluntarily provide written consent to participate in the study. If the subject is considered a minor at the time of collection of the informed consent, written consent will be obtained from a legally acceptable representative (guardian) in addition to that obtained from the subject. 2. Subject who has schizophrenia diagnosed by DSM-5, diagnostic criteria, and in the opinion of the Investigator has been clinically stable. 3. Subject who has body weight >= 40.0kg and body mass index (BMI) >= 18.5. 4. Female subjects who are premenopausal and of childbearing potential must have a negative serum pregnancy test result. 5. Female subjects who are of childbearing potential and male subjects whose partners are of childbearing potential must agree to use adequate and reliable contraception. other Exclusion Criteria: 1. Subjects who experienced an acute exacerbation of psychosis requiring change in antipsychotic medication (with reference to drug or dose) within 90 days before screening. 2. Subjects who become strongly affected by potent central nervous system depressants (including barbiturate) as considered by the Investigator. 3. Subjects who have any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study. 4. Subjects with active suicidal ideation or those with a suicide attempt history. 5. Subjects with a history or complication(s) of hypersensitivity to any medication. 6. Subjects with a history or complication(s) of malignant tumor within 5 years before screening, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Pituitary tumors of any duration are excluded. 7. Subjects who have previous or existing infection with human immunodeficiency virus (HIV) at screening. 8. Subjects who have a positive syphilis serological test, Hepatitis B virus surface (HBs) antigen or Hepatitis C virus (HCV) antibody at screening. other |
Country | Name | City | State |
---|---|---|---|
Japan | Kuramitsu Hospital | Fukuoka | |
Japan | NHO Hizen Psychiatric Center | Kanzaki | Saga-Ken |
Japan | Rainbow & Sea Hospital | Karatsu-shi | Saga-Ken |
Japan | NHO Ryukyu Hospital | Kunigami-gun | Okinawa-Ken |
Japan | Shiranui Hospital | Omuta-shi | Fukuoka-Ken |
Japan | Nishiurakai Keihan Hospital | Osaka-Fu | Moriguchi-shi |
Japan | Inuo Mental Care Hospital | Tosu | Saga |
Japan | Mental Support SOYOKAZE Hospital | Ueda-shi | Nagano-Ken |
Lead Sponsor | Collaborator |
---|---|
Sumitomo Pharma Co., Ltd. |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency of AEs, serious adverse events (SAEs), and AEs resulting in study discontinuation | adverse events (AEs), serious adverse events (SAEs) in cohort 1. | 18 days | |
Primary | Frequency of AEs, serious adverse events (SAEs), and AEs resulting in study discontinuation | adverse events (AEs), serious adverse events (SAEs) in cohort 2. | 21 days | |
Secondary | Plasma concentrations of SEP-363856 and its metabolite SEP-363854 | Plasma concentrations in cohort 1. | 18 days | |
Secondary | Plasma concentrations of SEP-363856 and its metabolite SEP-363854 | Plasma concentrations in cohort 2. | 21 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |